The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Human Papillomavirus Genotype Specificity of Hybrid Capture 2
Open accessAbstract
Hybrid Capture 2 (hc2), a clinical test for carcinogenic human papillomavirus (HPV) DNA, has proven to be a sensitive but only modestly specific predictor of cervical precancer and cancer risk. Some of its nonspecificity for clinical end points can be ascribed to cross-reactivity with noncarcinogenic HPV genotypes. However, the reference genotyping tests that have been used for these comparisons are also imperfect. We therefore sought to describe further the HPV genotype specificity of hc2 by comparing the hc2 results to paired results from two related PGMY09/11 L1 primer-based HPV genotyping assays: Linear Array (LA) and its prototype predecessor, the line blot assay (LBA). LA and LBA results were considered separately and combined (detection by either assay or both assays) for 37 individual HPV genotypes and HPV risk group categories (carcinogenic HPV > noncarcinogenic HPV > negative). Baseline specimens from 3,179 of 3,488 (91.5%) women referred to ALTS (a clinical trial to evaluate the management strategies for women with atypical squamous cells of undetermined significance [ASCUS] or low-grade squamous intraepithelial lesions) because of an ASCUS Papanicolaou smear were tested by all three assays. Among single-genotype infections with genotypes targeted by hc2 as detected by either PCR assay, HPV genotype 35 (HPV35) (86.4%), HPV56 (84.2%), and HPV58 (76.9%) were the most likely to test positive by hc2. Among single-genotype infections with genotypes not targeted by hc2 as detected by either assay, HPV82 (80.0%), HPV66 (60.0%) (recently classified as carcinogenic), HPV70 (59.1%), and HPV67 (56.3%) were the most likely to test positive by hc2. Among women who tested negative for carcinogenic HPV by both PCR tests and were positive for noncarcinogenic HPV by either test, 28% of women were hc2 positive. Conversely, 7.8% of all hc2-positive results in this population were due to cross-reactivity of hc2 with untargeted, noncarcinogenic HPV genotypes. In conclusion, hc2 cross-reacts with certain untargeted, noncarcinogenic HPV genotypes that are phylogenetically related to the targeted genotypes, but the degree of cross-reactivity may be less than previously reported.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Amplification of Genital Human Papillomaviruses
Gravitt, P. E., Peyton, C. L., Alessi, T. Q., Wheeler, C. M., Coutlée, F., Hildesheim, A., Schiffman, M. H., Scott, D. R., & Apple, R. J. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.1.357-361.2000 · Cited by 1,137
Self-citationSchiffman, M., Herrero, R., Hildesheim, A., Sherman, M. E., Bratti, M., Wacholder, S., Alfaro, M., Hutchinson, M., Morales, J., Greenberg, M. D., et al. (2000) · JAMA · doi:10.1001/jama.283.1.87 · Cited by 540
Self-citationManagement of women who test positive for high-risk types of human papillomavirus: the HART study
Cuzick, J., Szarewski, A., Cubie, H., Hulman, G., Kitchener, H., Luesley, D., McGoogan, E., Menon, U., Terry, G., Edwards, R., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14955-0 · Cited by 510 · cited 1×
“One test, Hybrid Capture 2 (hc2; Digene Corporation, Gaithersburg, MD), has received FDA approval for use in cervical cancer screening as described above; hc2 has proven to be reliable (6, 9, 14, 45) and sensitive for detection of cervical precancer (16, 17, 31, 32, 43).”
Method
Cited by
Human Papillomavirus Testing in the Prevention of Cervical Cancer
Schiffman, M., Wentzensen, N., Wacholder, S., Kinney, W., Gage, J. C., & Castle, P. E. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq562 · Cited by 759
Self-citationEvidence for Frequent Regression of Cervical Intraepithelial Neoplasia–Grade 2
Castle, P. E., Schiffman, M., Wheeler, C. M., & Solomon, D. (2009) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31818f5008 · Cited by 384
Self-citation2020 list of human papillomavirus assays suitable for primary cervical cancer screening
Arbyn, M., Simon, M., Peeters, E., Xu, L., Meijer, C. J. L. M., Berkhof, J., Cuschieri, K., Bonde, J., Ostrbenk Vanlencak, A., Zhao, F.-H., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.04.031 · Cited by 284
Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines
Egemen, D., Cheung, L. C., Chen, X., Demarco, M., Perkins, R. B., Kinney, W., Poitras, N., Befano, B., Locke, A., Guido, R. S., et al. (2020) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0000000000000529 · Cited by 260
Self-citationGravitt, P. E., Belinson, J. L., Salmeron, J., & Shah, K. V. (2011) · International Journal of Cancer · doi:10.1002/ijc.25974 · Cited by 106
Self-citation
Metadata
- Authors
- Castle, P. E., Solomon, D., Wheeler, C. M., Gravitt, P. E., Wacholder, S., & Schiffman, M.
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2008-08
- Volume
- 46
- Issue
- 8
- Pages
- 2595-2604
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- OpenAlex
- W2106852474
- Cited by
- 174
- References
- 3
- FWCI
- 14.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human Papillomavirus Genotype Specificity of Hybrid Capture 2. https://app.cochat.ai/papers/10.1128/jcm.00824-08
- The paper
- Castle, P. E., Solomon, D., Wheeler, C. M., Gravitt, P. E., Wacholder, S., & Schiffman, M. (2008). Human Papillomavirus Genotype Specificity of Hybrid Capture 2. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.00824-08
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.